Cold chain: difference between revisions
Diff·revision 67 → 68·07:47, 10 Sep 2025
Difference between revision 67 and revision 68 of Cold chain. 10 lines changed; the page grew by 1,902 bytes.
| Revision 67 — 19:55, 29 Aug 2025 CrudePeptidePearl (talk) consistent en dashes in ranges 24,029 bytes ±0 | Revision 68 — 07:47, 10 Sep 2025 CouplingCillian (talk) move table to the section it supports 25,931 bytes +1,902 | ||
|---|---|---|---|
| 154 | The defensibility is conditional and the conditions are not verifiable by the recipient. The glass transition temperature of a dry peptide matrix may be only tens of degrees above ambient; moisture ingress through a compromised closure lowers it further; and the material is unlikely ever to have had a stability programme establishing what it tolerates. A parcel that arrives warm has therefore experienced an exposure of unknown consequence rather than a demonstrably harmless one.{{r|ich_q1a,usp1079}} | 154 | The defensibility is conditional and the conditions are not verifiable by the recipient. The glass transition temperature of a dry peptide matrix may be only tens of degrees above ambient; moisture ingress through a compromised closure lowers it further; and the material is unlikely ever to have had a stability programme establishing what it tolerates. A parcel that arrives warm has therefore experienced an exposure of unknown consequence rather than a demonstrably harmless one.{{r|ich_q1a,usp1079}} |
| 155 | 155 | ||
| + | 156 | Community-collated reports of material used after warm transit exist, and consistently describe no observed change in effect. As evidence about degradation they are weak in specific, identifiable ways: there is no pre-exposure analytical baseline, no blinding, no measurement of the exposure itself, and the reported endpoint is subjective. Analytical [[Third-party testing|third-party testing]] of a post-transit sample can establish a purity figure, but without a matched pre-transit result it cannot attribute any deficit to transit rather than to manufacture.{{r|ppcold}} | |
| + | 157 | ||
| + | 158 | == Records and regulatory framing == | |
| + | 159 | In regulated distribution, the cold chain is a documented process, and the governing instruments describe records as much as equipment. | |
| + | 160 | ||
| + | 161 | The European Union guidelines on good distribution practice require that transport maintain labelled storage conditions, that vehicles and equipment be qualified, that temperature monitoring be applied on a risk basis, and that records be retained and available. Deviations must be investigated and their effect on product quality assessed before release for further distribution.{{r|eugdp2013}} | |
| + | 162 | ||
| + | 163 | The World Health Organization's model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products, published as Annex 9 to Technical Report Series 961, performs a similar function internationally and is written to be adoptable by national regulators. It is accompanied by technical supplements addressing individual operations — refrigerated storage, temperature mapping, qualification of shippers, and monitoring — that are the closest thing to a practical manual in the public literature.{{r|whotrs961}} | |
| + | 164 | ||
| 156 | == References == | 165 | == References == |
| 157 | {{reflist}} | 166 | {{reflist}} |
| ⋮ | ⋮ | ||
| 170 | <ref name="astm_d3103">ASTM D3103, ''Standard Test Method for Thermal Insulation Quality of Packages''. ASTM International.</ref> | 179 | <ref name="astm_d3103">ASTM D3103, ''Standard Test Method for Thermal Insulation Quality of Packages''. ASTM International.</ref> |
| 171 | <ref name="ich_q1a">International Council for Harmonisation, ''Q1A(R2): Stability Testing of New Drug Substances and Products'' (2003).</ref> | 180 | <ref name="ich_q1a">International Council for Harmonisation, ''Q1A(R2): Stability Testing of New Drug Substances and Products'' (2003).</ref> |
| + | 181 | <ref name="ppcold">PeptidePedia community transit-report tally, 2026 (self-reported, unblinded, exposure unmeasured, no pre-transit baselines; weak evidence — see [[Project:Sourcing_guidelines]]).</ref> | |
| 172 | 182 | ||
| 173 | == Further reading == | 183 | == Further reading == |